AIM: To study the ability of human adipose-derived mesenchymal stem cells (AMSCs) to survive over the short and long term, their biodistribution and their biosafety in vivo in tumor-prone environments. METHODS: We subcutaneously injected human AMSCs from different human donors into immunodeficient SCID mice over both short- (2 and 4 mo) and long- (17 mo) term in young, and aged tumor-prone mice. Presence of human cells was studied by immunohistochemistry and polymerase chain reaction analysis in all organs of injected mice. RESULTS: Subcutaneously injected AMSCs did not form teratomas at any time point. They did not migrate but remained at the site of injection regardless of animal age, and did not fuse with host cells in any organ examined. AMSCs survived in vivo for at least 17 mo after injection, and differentiated into fibroblasts of the subdermic connective tissue and into mature adipocytes of fat tissue, exclusively at the site of injection. CONCLUSION: Our results support the assertion that AMSC may be safe candidates for therapy when injected subcutaneously because of their long term inability to form teratomas.
AIM: To study the ability of human adipose-derived mesenchymal stem cells (AMSCs) to survive over the short and long term, their biodistribution and their biosafety in vivo in tumor-prone environments. METHODS: We subcutaneously injected human AMSCs from different human donors into immunodeficient SCIDmice over both short- (2 and 4 mo) and long- (17 mo) term in young, and aged tumor-prone mice. Presence of human cells was studied by immunohistochemistry and polymerase chain reaction analysis in all organs of injected mice. RESULTS: Subcutaneously injected AMSCs did not form teratomas at any time point. They did not migrate but remained at the site of injection regardless of animal age, and did not fuse with host cells in any organ examined. AMSCs survived in vivo for at least 17 mo after injection, and differentiated into fibroblasts of the subdermic connective tissue and into mature adipocytes of fat tissue, exclusively at the site of injection. CONCLUSION: Our results support the assertion that AMSC may be safe candidates for therapy when injected subcutaneously because of their long term inability to form teratomas.
Authors: Yuehua Jiang; Balkrishna N Jahagirdar; R Lee Reinhardt; Robert E Schwartz; C Dirk Keene; Xilma R Ortiz-Gonzalez; Morayma Reyes; Todd Lenvik; Troy Lund; Mark Blackstad; Jingbo Du; Sara Aldrich; Aaron Lisberg; Walter C Low; David A Largaespada; Catherine M Verfaillie Journal: Nature Date: 2002-06-20 Impact factor: 49.962
Authors: Patricia A Zuk; Min Zhu; Peter Ashjian; Daniel A De Ugarte; Jerry I Huang; Hiroshi Mizuno; Zeni C Alfonso; John K Fraser; Prosper Benhaim; Marc H Hedrick Journal: Mol Biol Cell Date: 2002-12 Impact factor: 4.138
Authors: Matus Studeny; Frank C Marini; Jennifer L Dembinski; Claudia Zompetta; Maria Cabreira-Hansen; Benjamin Nebiyou Bekele; Richard E Champlin; Michael Andreeff Journal: J Natl Cancer Inst Date: 2004-11-03 Impact factor: 13.506
Authors: Matus Studeny; Frank C Marini; Richard E Champlin; Claudia Zompetta; Isaiah J Fidler; Michael Andreeff Journal: Cancer Res Date: 2002-07-01 Impact factor: 12.701
Authors: Israel M Barbash; Pierre Chouraqui; Jack Baron; Micha S Feinberg; Sharon Etzion; Ariel Tessone; Liron Miller; Esther Guetta; Dov Zipori; Laurence H Kedes; Robert A Kloner; Jonathan Leor Journal: Circulation Date: 2003-08-04 Impact factor: 29.690
Authors: Steven W Shaw; Shao-Yu Peng; Ching-Chung Liang; Tzu-Yi Lin; Po-Jen Cheng; T'sang-T'ang Hsieh; Hao-Yu Chuang; Paolo De Coppi; Anna L David Journal: Sci Rep Date: 2021-04-28 Impact factor: 4.379
Authors: Cadenas-Martin Marta; Moratilla Adrian; Fernández-Delgado Jorge; Arnalich-Montiel Francisco; Maria P De Miguel Journal: Int J Mol Sci Date: 2021-11-05 Impact factor: 5.923
Authors: Francisco Arnalich-Montiel; Adrian Moratilla; Sherezade Fuentes-Julián; Veronica Aparicio; Marta Cadenas Martin; Gary Peh; Jodhbir S Mehta; Khadijah Adnan; Laura Porrua; Ane Pérez-Sarriegui; Maria P De Miguel Journal: PLoS One Date: 2019-11-21 Impact factor: 3.240